Pharmacokinetics of m-Chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: Implication for the pharmacodynamic profile

Pharmacopsychiatry

Volumn 37, Issue 4, 2004, Pages 180-188

  Feuchtl, A ^a   Bagli, M ^a   Stephan, R ^a   Frahnert, C ^a   Kolsch H ^a   Kuhn K U ^a   Rao, M L ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; CORTICOTROPIN; CYTOCHROME P450 2D6; HYDROCORTISONE; HYPOPHYSIS HORMONE; PLACEBO; PROLACTIN;

ADULT; ANXIETY; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; DRUG MECHANISM; DRUG METABOLISM; FEAR; GENDER; GENETIC VARIABILITY; HEALTH STATUS; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HUMAN EXPERIMENT; KINETICS; LIGHT; MALE; NOISE; NORMAL HUMAN; PRIORITY JOURNAL; SHIVERING; STATISTICAL SIGNIFICANCE; TIME; VOLUNTEER;

ADMINISTRATION, ORAL; ADRENOCORTICOTROPIC HORMONE; ADULT; ANXIETY; AUDITORY PERCEPTION; DIZZINESS; DOUBLE-BLIND METHOD; HUMANS; HYDROCORTISONE; INJECTIONS, INTRAVENOUS; MALE; PHOTOPHOBIA; PIPERAZINES; PROLACTIN; RADIOIMMUNOASSAY; SELF EFFICACY; SEROTONIN AGONISTS;

EID: 3142727136     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-827175     Document Type: Article

References (34)

1. Akaike A. Posterior probabilities for choosing a regression model. Annal Instit Math Stats 1965; 30: A9A13
2. Aitken RCB. Measurement of feelings using visual analogue scales. Royal Soc Med 1969; 62: 989-993
3. Bagli M, Süverkrüp R, Rao ML, Bode H. Mean input times of three oral chlorprothixene formulations assessed by an enhanced least-square deconvolution method. J Pharm Sci 1996; 85: 434-439
4. Bagli M, Süverkrüp R, Quadflieg R, Höflich G, Kasper S, Möller HJ, Langer M, Barlage U, Rao ML. Pharmacokinetic-pharmacodynamic modeling of tolerance to the prolactin-secreting effect of chlorprothixene after different modes of drug administration. J Pharmacol Exp Ther 1999; 291: 547-554
5. Barr LC, Goodman WK, Price LH, McDougle CJ, Charney DS. The serotonin hypothesis of obsessive compulsive disorder: Implications of pharmacologic challenge studies. J Clin Psychiatry 1992; 53 (4, Suppl.): 17-28
6. Bullinger M, Heinisch M, Ludwig M, Geier S. Skalen zur Erfassung des Wohlbefindens: Psychometrische Analysen zum "Profile of Mood States" (POMS) und zum "Psychological General Well-Being Index" (PGWB). Z Diff Diag Psychol 1990; 11: 53-61
7. Charney DS, Woods SW, Goodman WK, Heninger GR. Serotonin function in anxiety. II. Effects of the serotonin agonist mCPP in panic disorder patients and healthy subjects. Psychopharmacology 1987; 92: 14-24
8. Cutler DJ. Theory of the mean absorption time, an adjunct to conventional bioavailability studies. J Pharm Pharmacol 1978; 30: 476-478
9. Eichelbaum M, Bertilsson L, Sawe J, Zekorn C Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther 1982; 31: 184-186
10. Gabrielson J, Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. Stockholm: Swedish Pharmaceutical Press, 1994
11. Gibaldi M, Perrier D. Pharmacokinetics.; 2nd edn New York-Basel: Marcel Dekker, 1982
12. Gijsman HJ, van Gerven JMA, Tieleman MC, Schoemaker RC, Pieters MSM, Ferrari MD, Cohen AF, van Kempen GMJ. Pharmacokinetic and pharmacodynamic profile of oral and intravenous meta-chlorophenylpiperazine in healthy volunteers. J Clin Psychopharmacol 1998; 18: 289-295
13. Hamik A, Peroutka SJ. 1-(m-Chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biol Psychiatry 1989; 25: 569-575
14. Hamilton M. HAMA. Hamilton anxiety scale. In W. Guy (Ed). ECDEU Assessment Manual for Psychopharmacology Rockville: National Institute of Mental Health, 1976a: pp. 193-198
15. Hamilton M. HAMD. Hamilton depression scale. In W. Guy (Ed). ECDEU Assessment Manual for Psychopharmacology Rockville: National Institute of Mental Health, 1976b: pp. 179-192
16. Kahn RS, Davidson M. Serotonin receptor responsivity in schizophrenia. Int Clin Pharmacol 1993; 8 (Suppl. 2): 47-51
17. Kahn RS, Wetzler S. m-Chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry 1991; 30: 1139-1166
18. Kahn RS, Wetzler S, Asnis GM, King MA, Suckow RF, van Praag HM. Effects of m-chlorophenylpiperazine in normal subjects: a dose-response study. Psychopharmacology 1990; 100: 339-344
19. Kahn RS, Wetzler S, Asnis GM, King MA, Suckow RF, van Praag HM. Pituitary hormone responses to meta-chlorophenylpiperazine in panic disorder and healthy control subjects. Psychiatry Res 1991; 37: 25-34
20. 2C receptor agonist m-chlorophenylpiperazine in healthy male volunteers. Pharmacopsychiatry 2002; 35: 226-230
21. Lappalainen J, Zhang L, Dean M, Oz M, Ozaki N, Yu DH, Virkkunen M, Weight F, Linnoila M. Goldman D. Identification, expression, and pharmacology of Cys 23-Ser23 substitution in the human 5-HT2C receptor gene (HTR2C). Genomics 1995; 27: 274-279
22. Lawlor BA, Sunderland T, Hill JL, Mellow AM, Molchan SE, Mueller EA, Jacobsen FM, Murphy DL. Evidence for a decline with age in behavioral responsivity to the serotonin agonist, m-chlorophenylpiperazine, in healthy human subjects. Psychiatry Res 1989; 29: 1-10
23. Lawlor BA, Sunderland T, Mellow AM, Hill JL, Molchan SE, Murphy DL. Hyperresponsivity to the serotonin agonist, m-chlorophenylpiperazine, in Alzheimer's disease. Arch Gen Psychiatry 1989; 46: 542-549
24. Lewin HA, Stewart-Haynes JA. A simple method for DNA extraction from leukocytes for use in PCR. Biotechniques 1992; 13: 522-524
25. Lohmann PL, Bagli M, Krauss H, Müller DJ, Schulze TG, Held T, Fangerau H, Maier W, Rietschel M, Rao ML. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients. Pharmacopsychiatry, 2003 in press
26. Miller RL, DeVane CL. Analysis of trazodone and m-chlorophenylpiperazine in plasma and brain tissue by high-performance liquid chromatography. J Chromatogr 1986; 374: 388-393
27. Murphy DL, Mueller EA, Hill JL, Tolliver TJ, Jacobsen FM. Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers. Psychopharmacology 1989; 98: 275-282
28. Riegelmann S, Collier P. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokin Biopharm 1980; 8: 509-534
29. Rotzinger S, Fang J, Coutts RT, Baker GB. Human CYP2D6 and metabolism of m-chlorophenylpiperazine. Biol Psychiatry 1998; 44: 1185-1191
30. Schwartz PJ, Murphy DL, Wehr TA, Garcia-Borreguero D, Oren DA, Moul DE, Ozaki N, Snelbaker AJ, Rosenthal NE. Effects of meta-chlorophenylpiperazine infusions in patients with seasonal affective disorder and healthy control subjects. Arch Gen Psychiatry 1997; 54: 375-385
31. 3 agonist, BRL 46470 does not attenuate m-chlorophenylpiperazine (mCPP)-induced changes in human volunteers. Biol Psychiatry 1994; 36: 309-316
32. Silverstone PH, Rue JE, Franklin M, Hallis K, Camplin G, Laver D, Cowen PJ. The effects of administration of mCPP on psychological, cognitive, cardiovascular, hormonal and MHPG measurements in human volunteers. Int Clin Psychopharmacol 1994; 9: 173 -178
33. Yamaoka K, Nakagawa T, Uno T. Statistical moments in pharmacokinetics. J Pharmacokin Biopharm 1978a; 6: 547-558
34. Yamaoka K, Nakagawa T, Uno T. Application of the Akaike information criterion AlG in the evaluation of linear pharmacokinetics. J Pharmacokin Biopharm 1978b; 6:165-175